Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention.

Autor: Nykamp MJ; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA., Zorumski CF; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA., Reiersen AM; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA., Nicol GE; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA., Cirrito J; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Lenze EJ; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Jazyk: angličtina
Zdroj: Pharmacopsychiatry [Pharmacopsychiatry] 2022 Jan; Vol. 55 (1), pp. 24-29. Date of Electronic Publication: 2021 Dec 07.
DOI: 10.1055/a-1686-9620
Abstrakt: Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.
Competing Interests: The authors declare that they have no conflict of interest.
(Thieme. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: